Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Management of a patient with a double EGFR and MET anomaly by combined treatment].

Revue des maladies respiratoires - 1 Jun 2020

Jénot L, Rouquette I, Mazieres J

Abstract excerpt

INTRODUCTION: Lung cancer displays molecular anomalies for which targeted therapies are the standard first line treatment. The EGFR mutation is present in 10% of cases of non-small cell lung cancer in Caucasians. MET amplification associated with an exon 19 EGFR mutation has been identified though it is usually regarded as a mechanism of resistance. CASE REPORT: We report the case of a 74-year-old never-smoking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Crizotinib

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gene Amplification

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 32430158
DOI: 10.1016/j.rmr.2020.03.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Management of a patient with a double EGFR and MET anomaly by combined treatment].PMID 32430158Read ↗

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.Semantic proximity Read ↗

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].Semantic proximity Read ↗

[Driver gene mutation and targeted therapy of lung cancer].Semantic proximity Read ↗

[Interest of crizotinib in a lung cancer patient with de novo amplification of MET].Semantic proximity Read ↗

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read ↗

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report.Semantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

[Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].Semantic proximity Read ↗

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.Semantic proximity Read ↗

[Pulmonary adenocarcinoma with double mutation EGFR: L858R and G719X].Semantic proximity Read ↗

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.